iTeos Therapeutics, Inc.
ITOS
Cena:
Valuace
70
Růst
0
Zdraví
55
Zprávy
Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
SHAREHOLDER INVESTIGATION: HALPER SADEH LLC INVESTIGATES ITOS AND KLG ON BEHALF OF SHAREHOLDERS
20-08-2025
NEW YORK , AUG. 20, 2025 /PRNEWSWIRE/ -- HALPER SADEH LLC, AN INVESTOR RIGHTS LAW FIRM, IS INVESTIGA...
Více zde
ITEOS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF ITEOS THERAPEUTICS, INC. - ITOS
19-08-2025
NEW YORK AND NEW ORLEANS, AUG. 19, 2025 (GLOBE NEWSWIRE) -- FORMER ATTORNEY GENERAL OF LOUISIANA CHA...
Více zde
ITEOS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF ITEOS THERAPEUTICS, INC. - ITOS
22-07-2025
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, ...
Více zde
SHAREHOLDER INVESTIGATION: HALPER SADEH LLC INVESTIGATES ITOS AND ZIMV ON BEHALF OF SHAREHOLDERS
21-07-2025
NEW YORK, JULY 21, 2025 (GLOBE NEWSWIRE) -- HALPER SADEH LLC, AN INVESTOR RIGHTS LAW FIRM, IS INVEST...
Více zde
ALERT: ROWLEY LAW PLLC IS INVESTIGATING PROPOSED ACQUISITION OF ITEOS THERAPEUTICS, INC.
21-07-2025
NEW YORK , JULY 21, 2025 /PRNEWSWIRE/ -- ROWLEY LAW PLLC IS INVESTIGATING POTENTIAL SECURITIES LAW ...
Více zde
$HAREHOLDER ALERT: THE M&A CLASS ACTION FIRM ANNOUNCES AN INVESTIGATION OF ITEOS THERAPEUTICS, INC. (NASDAQ: ITOS)
21-07-2025
NEW YORK, JULY 21, 2025 (GLOBE NEWSWIRE) -- CLASS ACTION ATTORNEY JUAN MONTEVERDE WITH MONTEVERDE & ...
Více zde
ITOS STOCK ALERT: HALPER SADEH LLC IS INVESTIGATING WHETHER THE SALE OF ITEOS THERAPEUTICS, INC. IS FAIR TO SHAREHOLDERS
21-07-2025
NEW YORK--(BUSINESS WIRE)--HALPER SADEH LLC, AN INVESTOR RIGHTS LAW FIRM, IS INVESTIGATING WHETHER T...
Více zde
ITEOS THERAPEUTICS ENTERS INTO AGREEMENT TO BE ACQUIRED BY CONCENTRA BIOSCIENCES FOR $10.047 IN CASH PER SHARE PLUS A CONTINGENT VALUE RIGHT
21-07-2025
WATERTOWN, MASS. AND GOSSELIES, BELGIUM, JULY 21, 2025 (GLOBE NEWSWIRE) -- ITEOS THERAPEUTICS, INC. ...
Více zde
ITEOS THERAPEUTICS ANNOUNCES ITS INTENTION TO WIND DOWN OPERATIONS
28-05-2025
- BOARD OF DIRECTORS INTENDS TO CEASE OPERATIONS - COMPANY TO FOCUS EFFORTS ON SELECTING BEST PATH T...
Více zde
ITEOS REPORTS TOPLINE INTERIM RESULTS FROM GALAXIES LUNG-201 STUDY OF BELRESTOTUG + DOSTARLIMAB IN FIRST-LINE, PD-L1 HIGH NON-SMALL CELL LUNG CANCER PATIENTS
13-05-2025
– GALAXIES LUNG-201 DID NOT MEET ESTABLISHED CRITERIA FOR CLINICALLY MEANINGFUL IMPROVEMENTS IN P...
Více zde
ITEOS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES
28-04-2025
- TOPLINE INTERIM DATASET FROM GALAXIES LUNG-201 WITH >240 PATIENTS ANTICIPATED IN 2Q25 - INTERIM DA...
Více zde
ITEOS TO PRESENT PRECLINICAL DATA ON POTENTIAL BEST-IN-CLASS ANTI-TREM2 ANTIBODY, EOS-215, AND NOVEL PTPN1/2 INHIBITOR AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING 2025
25-03-2025
WATERTOWN, MASS. AND GOSSELIES, BELGIUM, MARCH 25, 2025 (GLOBE NEWSWIRE) -- ITEOS THERAPEUTICS, INC....
Více zde
ITEOS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES
05-03-2025
- TOPLINE INTERIM DATASET FROM GALAXIES LUNG-201 WITH >240 PATIENTS ANTICIPATED IN 2Q25 - INTERIM DA...
Více zde
ITEOS THERAPEUTICS PRESENTS INTERIM A2A-005 CLINICAL TRIAL DATA, TRANSLATIONAL, AND PRECLINICAL DATA FROM INUPADENANT AT ESMO IMMUNO-ONCOLOGY CONGRESS
12-12-2024
- INUPADENANT + CARBOPLATIN/PEMETREXED IN PHASE 2 A2A-005 TRIAL DEMONSTRATED A 63.9% OVERALL RESPONS...
Více zde
ITEOS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
26-11-2024
WATERTOWN, MASS. AND GOSSELIES, BELGIUM, NOV. 26, 2024 (GLOBE NEWSWIRE) -- ITEOS THERAPEUTICS, INC. ...
Více zde
ITEOS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES
12-11-2024
- EMA GRANTED CLEARANCE TO ADVANCE BELRESTOTUG 400MG + DOSTARLIMAB AS RECOMMENDED PHASE 3 DOSE AND A...
Více zde
ITEOS ANNOUNCES CLINICALLY MEANINGFUL OBJECTIVE RESPONSE RATE OBSERVED AT EVERY DOSE IN FOLLOW-UP INTERIM ANALYSIS OF GALAXIES LUNG-201 STUDY OF BELRESTOTUG + DOSTARLIMAB IN FIRST-LINE, PD-L1 HIGH NON-SMALL CELL LUNG CANCER PATIENTS
14-09-2024
- CLINICALLY MEANINGFUL OBJECTIVE RESPONSE RATE (ORR) OF 63.3-76.7% OBSERVED WITH BELRESTOTUG + DOST...
Více zde
ITEOS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
28-08-2024
WATERTOWN, MASS. AND GOSSELIES, BELGIUM, AUG. 28, 2024 (GLOBE NEWSWIRE) -- ITEOS THERAPEUTICS, INC. ...
Více zde
ITEOS THERAPEUTICS ANNOUNCES LATE-BREAKING ORAL PRESENTATION OF PHASE 2 GALAXIES LUNG-201 INTERIM DATA AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY CONGRESS 2024
20-08-2024
WATERTOWN, MASS. AND GOSSELIES, BELGIUM, AUG. 20, 2024 (GLOBE NEWSWIRE) -- ITEOS THERAPEUTICS, INC. ...
Více zde
ITEOS THERAPEUTICS ANNOUNCES APPOINTMENT OF DAVID FELTQUATE AS CHIEF MEDICAL OFFICER
05-08-2024
WATERTOWN, MASS. AND GOSSELIES, BELGIUM, AUG. 05, 2024 (GLOBE NEWSWIRE) -- ITEOS THERAPEUTICS, INC...
Více zde
ITEOS ANNOUNCES FIRST PATIENT DOSED IN GALAXIES LUNG-301 PHASE 3 STUDY, EARNING $35 MILLION IN MILESTONES FROM GSK
08-07-2024
WATERTOWN, MASS. AND GOSSELIES, BELGIUM, JULY 08, 2024 (GLOBE NEWSWIRE) -- ITEOS THERAPEUTICS, INC. ...
Více zde
ITEOS AND GSK INITIATE GALAXIES LUNG-301 PHASE 3 STUDY, ASSESSING BELRESTOTUG AND DOSTARLIMAB IN PREVIOUSLY UNTREATED, UNRESECTABLE LOCALLY ADVANCED / METASTATIC PD-L1 SELECTED NON-SMALL CELL LUNG CANCER
17-06-2024
WATERTOWN, MASS. AND GOSSELIES, BELGIUM, JUNE 17, 2024 (GLOBE NEWSWIRE) -- ITEOS THERAPEUTICS, INC. ...
Více zde
ITEOS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES
10-05-2024
- BELRESTOTUG + DOSTARLIMAB EXCEEDED PRE-DEFINED EFFICACY CRITERIA FOR CLINICALLY RELEVANT ACTIVITY ...
Více zde
ITEOS THERAPEUTICS ANNOUNCES $120 MILLION REGISTERED DIRECT OFFERING
10-05-2024
- LED BY EXISTING INVESTORS RA CAPITAL MANAGEMENT AND BOXER CAPITAL - PURCHASE PRICE OF $17.50 REPRE...
Více zde
ITEOS PRESENTS EOS-984 PRECLINICAL DATA DEMONSTRATING RESTORATION OF T CELL ACTIVITY FROM ADENOSINE SUPPRESSION AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING 2024
07-04-2024
WATERTOWN, MASS. AND GOSSELIES, BELGIUM, APRIL 07, 2024 (GLOBE NEWSWIRE) -- ITEOS THERAPEUTICS, INC....
Více zde
ITEOS APPOINTS ONCOLOGY VETERAN JILL DESIMONE TO ITS BOARD OF DIRECTORS
06-03-2024
WATERTOWN, MASS. AND GOSSELIES, BELGIUM, MARCH 06, 2024 (GLOBE NEWSWIRE) -- ITEOS THERAPEUTICS, INC....
Více zde
ITEOS REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES
06-03-2024
- MULTIPLE CLINICAL MILESTONES ACROSS PORTFOLIO ANTICIPATED IN 2024, INCLUDING TWO PHASE 2 TRIALS AS...
Více zde
ITEOS TO HIGHLIGHT PRECLINICAL DATA ON FIRST-IN-CLASS EOS-984 TARGETING ENT1 AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING 2024
05-03-2024
WATERTOWN, MASS. AND GOSSELIES, BELGIUM, MARCH 05, 2024 (GLOBE NEWSWIRE) -- ITEOS THERAPEUTICS, INC....
Více zde
ITEOS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
01-03-2024
WATERTOWN, MASS. AND GOSSELIES, BELGIUM, MARCH 01, 2024 (GLOBE NEWSWIRE) -- ITEOS THERAPEUTICS, INC....
Více zde
ITEOS TO PRESENT AT THE PIPER SANDLER 35TH ANNUAL HEALTHCARE CONFERENCE
21-11-2023
WATERTOWN, MASS. AND GOSSELIES, BELGIUM, NOV. 21, 2023 (GLOBE NEWSWIRE) -- ITEOS THERAPEUTICS, INC. ...
Více zde
| Datum | Typ | Otevřít EDGAR | Stáhnout dokument |
|---|---|---|---|
| 2025-08-29 01:00:00 | 8-K |  | Stáhnout |
| 2025-08-29 00:00:00 | 8-K | | Stáhnout |
| 2025-08-06 01:00:00 | 10-Q | | Stáhnout |
| 2025-08-06 00:00:00 | 10-Q | | Stáhnout |
| 2025-07-21 01:00:00 | 8-K | | Stáhnout |
| 2025-07-21 00:00:00 | 8-K | | Stáhnout |
| 2025-06-17 01:00:00 | 8-K | | Stáhnout |
| 2025-06-17 00:00:00 | 8-K | | Stáhnout |
| 2025-06-05 01:00:00 | 8-K | | Stáhnout |
| 2025-06-05 00:00:00 | 8-K | | Stáhnout |
| 2025-05-28 01:00:00 | 8-K | | Stáhnout |
| 2025-05-28 00:00:00 | 8-K | | Stáhnout |
| 2025-05-13 01:00:00 | 8-K | | Stáhnout |
| 2025-05-13 00:00:00 | 8-K | | Stáhnout |
| 2025-04-28 01:00:00 | 10-Q | | Stáhnout |
| 2025-04-28 00:00:00 | 10-Q | | Stáhnout |
| 2025-03-05 00:00:00 | 10-K | | Stáhnout |
| 2025-03-04 23:00:00 | 10-K | | Stáhnout |
| 2025-01-13 00:00:00 | 8-K | | Stáhnout |
| 2025-01-12 23:00:00 | 8-K | | Stáhnout |
| 2024-11-12 00:00:00 | 10-Q | | Stáhnout |
| 2024-11-11 23:00:00 | 10-Q | | Stáhnout |
| 2024-11-04 00:00:00 | 8-K | | Stáhnout |
| 2024-11-03 23:00:00 | 8-K | | Stáhnout |
| 2024-09-16 01:00:00 | 8-K | | Stáhnout |
| 2024-09-16 00:00:00 | 8-K | | Stáhnout |
| 2024-08-08 01:00:00 | 10-Q | | Stáhnout |
| 2024-08-08 00:00:00 | 10-Q | | Stáhnout |
| 2024-06-13 01:00:00 | 8-K | | Stáhnout |
| 2024-06-13 00:00:00 | 8-K | | Stáhnout |
| 2024-05-13 01:00:00 | 8-K | | Stáhnout |
| 2024-05-13 00:00:00 | 8-K | | Stáhnout |
| 2024-05-10 01:00:00 | 10-Q | | Stáhnout |
| 2024-05-10 00:00:00 | 10-Q | | Stáhnout |
| 2024-03-06 00:00:00 | 10-K | | Stáhnout |
| 2024-03-05 23:00:00 | 10-K | | Stáhnout |
| 2024-01-10 00:00:00 | 8-K | | Stáhnout |
| 2024-01-09 23:00:00 | 8-K | | Stáhnout |
| 2023-12-07 00:00:00 | 8-K | | Stáhnout |
| 2023-12-06 23:00:00 | 8-K | | Stáhnout |
| 2023-11-07 00:00:00 | 10-Q | | Stáhnout |
| 2023-11-06 23:00:00 | 10-Q | | Stáhnout |
| 2023-08-08 01:00:00 | 10-Q | | Stáhnout |
| 2023-08-08 00:00:00 | 10-Q | | Stáhnout |
| 2023-06-26 01:00:00 | 8-K | | Stáhnout |
| 2023-06-26 00:00:00 | 8-K | | Stáhnout |
| 2023-06-20 01:00:00 | 8-K | | Stáhnout |
| 2023-06-20 00:00:00 | 8-K | | Stáhnout |
| 2023-05-10 01:00:00 | 10-Q | | Stáhnout |
| 2023-05-10 00:00:00 | 10-Q | | Stáhnout |
| 2023-03-15 00:00:00 | 10-K | | Stáhnout |
| 2023-03-14 23:00:00 | 10-K | | Stáhnout |
| 2023-03-10 00:00:00 | 8-K | | Stáhnout |
| 2023-03-09 23:00:00 | 8-K | | Stáhnout |
| 2023-02-03 00:00:00 | 8-K | | Stáhnout |
| 2023-02-02 23:00:00 | 8-K | | Stáhnout |
| 2023-01-09 00:00:00 | 8-K | | Stáhnout |
| 2023-01-08 23:00:00 | 8-K | | Stáhnout |
| 2022-11-10 00:00:00 | 10-Q | | Stáhnout |
| 2022-11-09 23:00:00 | 10-Q | | Stáhnout |
| 2022-08-10 01:00:00 | 10-Q | | Stáhnout |
| 2022-08-10 00:00:00 | 10-Q | | Stáhnout |
| 2022-06-13 01:00:00 | 8-K | | Stáhnout |
| 2022-06-13 00:00:00 | 8-K | | Stáhnout |
| 2022-05-12 01:00:00 | 10-Q | | Stáhnout |
| 2022-05-12 00:00:00 | 10-Q | | Stáhnout |
| 2022-03-23 00:00:00 | 10-K | | Stáhnout |
| 2022-03-22 23:00:00 | 10-K | | Stáhnout |
| 2022-01-11 00:00:00 | 8-K | | Stáhnout |
| 2022-01-10 23:00:00 | 8-K | | Stáhnout |
| 2021-11-10 00:00:00 | 10-Q | | Stáhnout |
| 2021-11-09 23:00:00 | 10-Q | | Stáhnout |
| 2021-08-11 01:00:00 | 10-Q | | Stáhnout |
| 2021-08-11 00:00:00 | 10-Q | | Stáhnout |
| 2021-08-10 01:00:00 | 8-K | | Stáhnout |
| 2021-08-10 00:00:00 | 8-K | | Stáhnout |
| 2021-07-28 01:00:00 | 8-K | | Stáhnout |
| 2021-07-28 00:00:00 | 8-K | | Stáhnout |
| 2021-06-16 01:00:00 | 8-K | | Stáhnout |
| 2021-06-16 00:00:00 | 8-K | | Stáhnout |
| 2021-06-14 01:00:00 | 8-K | | Stáhnout |
| 2021-06-14 00:00:00 | 8-K | | Stáhnout |
| 2021-05-13 01:00:00 | 8-K | | Stáhnout |
| 2021-05-13 01:00:00 | 10-Q | | Stáhnout |
| 2021-05-13 00:00:00 | 8-K | | Stáhnout |
| 2021-05-13 00:00:00 | 10-Q | | Stáhnout |
| 2021-05-04 01:00:00 | 8-K | | Stáhnout |
| 2021-05-04 00:00:00 | 8-K | | Stáhnout |
| 2021-04-12 01:00:00 | 8-K | | Stáhnout |
| 2021-04-12 00:00:00 | 8-K | | Stáhnout |
| 2021-03-24 00:00:00 | 8-K | | Stáhnout |
| 2021-03-24 00:00:00 | 10-K | | Stáhnout |
| 2021-03-23 23:00:00 | 8-K | | Stáhnout |
| 2021-03-23 23:00:00 | 10-K | | Stáhnout |
| 2021-03-22 00:00:00 | 8-K | | Stáhnout |
| 2021-03-21 23:00:00 | 8-K | | Stáhnout |
| 2021-01-11 00:00:00 | 8-K | | Stáhnout |
| 2021-01-10 23:00:00 | 8-K | | Stáhnout |
| 2020-11-12 00:00:00 | 8-K | | Stáhnout |
| 2020-11-12 00:00:00 | 10-Q | | Stáhnout |
| 2020-11-11 23:00:00 | 8-K | | Stáhnout |
| 2020-11-11 23:00:00 | 10-Q | | Stáhnout |
| 2020-09-01 01:00:00 | 8-K | | Stáhnout |
| 2020-09-01 01:00:00 | 10-Q | | Stáhnout |
| 2020-09-01 00:00:00 | 8-K | | Stáhnout |
| 2020-09-01 00:00:00 | 10-Q | | Stáhnout |
| 2020-07-28 01:00:00 | 8-K | | Stáhnout |
| 2020-07-28 00:00:00 | 8-K | | Stáhnout |
